Pyridoxamine Attenuates Doxorubicin-Induced Cardiomyopathy without Affecting Its Antitumor Effect on Rat Mammary Tumor Cells
Cells · 09.01.2024 · 13 (2) · 120
DOI: 10.3390/cells13020120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 09.01.2024. Verfasst von Sibren Haesen und 5 weiteren Autor:innen. Beteiligte Einrichtung: UHasselt, Cardio & Organ Systems (COST), BIOMED, Agoralaan, 3590 Diepenbeek, Belgium. Hauptthemen laut MEDLINE: Cardiomyopathies, Mammary Neoplasms, Animal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Foundation - Flanders, Flemish Fund for Scientific Research (FWO Vlaanderen, Brussels, Belgium), UHasselt Special Research Fund.
Abstract (Originalsprache)
Doxorubicin (DOX) is commonly used in cancer treatment but associated with cardiotoxicity. Pyridoxamine (PM), a vitamin B6 derivative, could be a cardioprotectant. This study investigated the effect of PM on DOX cardiotoxicity and DOX antitumor effectiveness. Sprague Dawley rats were treated intravenously with DOX (2 mg/kg/week) or saline over eight weeks. Two other groups received PM via oral intake (1 g/L in water bottles) next to DOX or saline. Echocardiography was performed after eight weeks. PM treatment significantly attenuated the DOX-induced reduction in left ventricular ejection fraction (72 ± 2% vs. 58 ± 3% in DOX; p < 0.001) and increase in left ventricular end-systolic volume (0.24 ± 0.02 µL/cm2 vs. 0.38 ± 0.03 µL/cm2 in DOX; p < 0.0001). Additionally, LA7 tumor cells were exposed to DOX, PM, or DOX and PM for 24 h, 48 h, and 72 h. Cell viability, proliferation, cytotoxicity, and apoptosis were assessed. DOX significantly reduced LA7 cell viability and proliferation (p < 0.0001) and increased cytotoxicity (p < 0.05) and cleaved caspase-3 (p < 0.001). Concomitant PM treatment did not alter the DOX effect on LA7 cells. In conclusion, PM attenuated DOX-induced cardiomyopathy in vivo without affecting the antitumor effect of DOX in vitro, highlighting PM as a promising cardioprotectant for DOX-induced cardiotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UHasselt, Cardio & Organ Systems (COST), BIOMED, Agoralaan, 3590 Diepenbeek, Belgium.
ORCID-Profile: Sibren Haesen, Ellen Heeren, Virginie Bito
Förderung
- Research Foundation - Flanders
- Flemish Fund for Scientific Research (FWO Vlaanderen, Brussels, Belgium)
- UHasselt Special Research Fund
Zitieren
APA
Haesen, S., Verghote, E., Heeren, E., Wolfs, E., Deluyker, D., & Bito, V. (2024). Pyridoxamine Attenuates Doxorubicin-Induced Cardiomyopathy without Affecting Its Antitumor Effect on Rat Mammary Tumor Cells. Cells, 13(2), 120. https://doi.org/10.3390/cells13020120
Vancouver
Haesen S, Verghote E, Heeren E, Wolfs E, Deluyker D, Bito V. Pyridoxamine Attenuates Doxorubicin-Induced Cardiomyopathy without Affecting Its Antitumor Effect on Rat Mammary Tumor Cells. Cells. 2024;13(2):120. doi:10.3390/cells13020120
BibTeX
@article{Haesen2024,
author = {Haesen, Sibren and Verghote, Eline and Heeren, Ellen and Wolfs, Esther and Deluyker, Dorien and Bito, Virginie},
title = {Pyridoxamine Attenuates Doxorubicin-Induced Cardiomyopathy without Affecting Its Antitumor Effect on Rat Mammary Tumor Cells},
journal = {Cells},
year = {2024},
volume = {13},
number = {2},
pages = {120},
doi = {10.3390/cells13020120}
}
EUVIMED